Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BeOne Medicines Ltd ( (HK:6160) ) has provided an update.
BeOne Medicines has published an updated company information sheet dated March 13, 2026, detailing its current waivers and exemptions from certain provisions of the Hong Kong Listing Rules and related ordinances. The board affirms responsibility for the accuracy and completeness of this information and undertakes to issue revised disclosures when material changes occur.
The disclosed waivers cover areas such as the company’s articles, use of U.S. GAAP and specific audit standards, share placements to connected persons, exercise prices under its share option scheme, and collaboration agreements with partners including Amgen. Additional exemptions relate to listing arrangements for RMB shares and the handling of corporate communications, clarifying the company’s regulatory flexibility and ongoing compliance framework for investors and other stakeholders.
The most recent analyst rating on (HK:6160) stock is a Hold with a HK$200.00 price target. To see the full list of analyst forecasts on BeOne Medicines Ltd stock, see the HK:6160 Stock Forecast page.
More about BeOne Medicines Ltd
BeOne Medicines Ltd is a Hong Kong-listed company in the pharmaceutical and biotechnology sector, trading under stock code 06160 and short name BEONE MEDICINES. The company operates under the regulatory framework of the Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited, and provides periodic public information updates on its corporate and listing arrangements.
Average Trading Volume: 3,617,052
Technical Sentiment Signal: Buy
Current Market Cap: HK$282.3B
Learn more about 6160 stock on TipRanks’ Stock Analysis page.